It's a bit brief, but I know that some of you have treatment decisions that depend on this result and are eagerly awaiting the details.
"Roche and Breast International Group (BIG)(1) announced that targeted anti-cancer therapy Herceptin (trastuzumab) achieved a highly significant 46% reduction in the risk of cancer coming back for women with early-stage HER2-positive breast cancer. HERA (HERceptin Adjuvant), an international, phase III study, investigated treatment with Herceptin for 12 or 24 months versus no treatment (observation) in patients who had previously undergone a range of surgical, chemotherapy and/or radiotherapy interventions. HER2-positive breast cancer is a particularly aggressive form of the disease which affects approximately 20 - 30% of women with breast cancer(2), so early and accurate determination of HER2 status is an essential step in the management of the disease."
For more info see:
Herceptin Delivers Impressive Improvement in Disease-Free Survival for Women With Early-Stage HER2-Positive Breast Cancer
This press release is also available in Spanish:
http://www.prnewswire.co.uk/cgi/news/release?id=146050
in German:
http://www.prnewswire.co.uk/cgi/news/release?id=146049
and in French:
http://www.prnewswire.co.uk/cgi/news/release?id=146048
Threaded Mode